GC Green Cross announced on June 25 that it recently held the 2026 R&D Portfolio Review Workshop and redefined its top-priority pipelines to drive future growth.

GC Green Cross Focuses R&D Pipeline, Declares 'THE FAB FIVE' as Top Priorities View original image

The company named its five core assets, which will receive company-wide focus, as 'THE FAB FIVE.' Inspired by the legendary group of five freshmen known as the Fabulous Five, who changed the paradigm of U.S. college basketball with their overwhelming talent, this name reflects the company's determination to lead a paradigm shift in R&D.


GC Green Cross carefully selected the 'THE FAB FIVE' projects by evaluating their high market value and strategic importance from multiple perspectives. The five pipelines chosen for this initiative are: ▲20% SCIG (GC5136B) ▲mCOVID vaccine (GC4006A) ▲EBV subunit vaccine (GC1140B) ▲Fabry disease treatment (GC1134A) ▲EGFR X cMET ADC (GC1148A). The company has expanded its pipeline from its traditional strengths in plasma-derived products and premium vaccines to include cutting-edge oncology areas.


Additionally, GC Green Cross is stably operating a variety of vaccine and rare disease treatment pipelines beyond THE FAB FIVE and has built a robust portfolio of early-stage, immune-focused projects utilizing various modalities. The company has also completed the establishment of an internal system that enables continuous evaluation and prioritization of its pipelines.


Jaeuk Jeong, Head of R&D at GC Green Cross, stated, "We are accumulating meaningful experience, such as obtaining U.S. approval for Aliglo, the world's first approval of a recombinant anthrax vaccine, and achieving global technological milestones for a shingles vaccine candidate." He added, "We will strengthen our R&D capabilities and make strategic investments centered around THE FAB FIVE, turning this into sustainable growth momentum."



Meanwhile, GC Green Cross recently signed a joint research agreement with AbClon to use the mRNA-LNP platform for in vivo CAR-T therapy, further accelerating the expansion of its pipeline.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing